TORONTO, March 18, 2013 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign" or the "Company") today announced the following:
Appointment of a new US Sales Agent, opening order of 100 Pulsewave™ devices:
Clear2there LLC, a leading provider of advanced video surveillance, smart-home, smart-business, communications, and machine-to-machine (M2M) solutions for service providers and enterprises, announced it has joined forces with Biosign to address the burgeoning market for smart healthcare and monitoring solutions.
As a part of a sales agency agreement with Biosign, Clear2there will begin offering Biosign's Pulsewave™ medical device technology across the North American market. Under the terms of the agreement, Clear2there plans to integrate the Pulsewave™ software client with their Viewbiquity Content Interface as well as their Edge Gateway device. Clear2there will offer the joint solution as a part of a highly-regarded smart services package being delivered to subscribers by local telephone and data service providers across North America. Biosign's FDA-cleared Pulsewave™ monitor captures blood pressure and heart rate readings and will leverage the Viewbiquity Cloud Application Suite provided by Clear2there for connectivity to the Biosign Cloud Diagnostics™ services platform. Initially, Clear2there plans to deploy up to one hundred Pulsewave™ devices and activate the related monitoring services as a part of its ongoing program of service provider evaluation currently underway in over 65 Viewbiquity pilot projects in the United States.
"In our conversations with many local service providers, we have observed a sharp increase in demand for smart health monitoring and other telemedicine services that enable people to remain in their homes as they age," said Craig Steen, president and chief executive officer of Clear2there. "Biosign's Pulsewave™ product is a highly recognized vital signs measurement solution that is very easy to use by both seniors and people with disabilities.
The Biosign Pulsewave™ Monitor is an end-to-end solution for non-invasive monitoring, analysis and reporting of health data. The Pulsewave™ cuff painlessly captures the pulse waveform from a person's radial artery and transmits it to the secure Biosign servers in the cloud, in this case through the Viewbiquity Edge Gateway at the consumer's home. Biosign algorithms are employed to analyze the data in seconds in order to generate reports that include blood pressure and other vital sign measurements. In addition, online Pulsewave™ analysis and reporting tools give patients and healthcare providers secure access to real-time and historical health information.
According to Biosign chief executive officer Robert Kaul, the data collected during an examination can provide the basis for precise blood pressure results as well as a broad range of other cardiovascular measurements. "During a simple and painless user-initiated session, in addition to blood pressure, the Pulsewave™ system can determine pulse rate and variability, and can also detect anomalies in circulatory function that may lead to a doctor's consultation," said Kaul. "The data is not only analyzed as quickly as it is received, but historical measurements can be charted and analyzed for trends and changes that may indicate a need for medical intervention or attention, making the system an excellent screening tool."
"Smart-healthcare and monitoring is one of the fastest growing segments in this marketplace, and we are excited to enable local service providers to meet their customers' needs with an innovative solution such as Pulsewave™," noted Steen. "We anticipate that there will be intense interest in this solution from consumers and family members who seek a safe, reliable and flexible solution to monitor the well-being of loved ones."
Clear2there is an innovative, full-service provider of market-leading smart-home and smart-business solutions for service providers and feature-rich video surveillance, communications, and M2M solutions for businesses. Based in Oklahoma City and Deerfield Beach, Florida, Clear2there works with national distribution partners, and offers a team of dedicated support staff to assist in all phases of implementation. For additional information, visit www.clear2there.com.
Appointment of new CFO:
The Company announced that it has appointed Mr. William Randolph (Randy) Polley, CA as Chief Financial Officer, to replace Mr. Frank Iadipaolo, CA who had earlier submitted his resignation in order to spend more time on his other business interests.
Mr. Polley will oversee Biosign's finance and accounting functions, utilizing extensive financial management and corporate development experience gained through working with small and mid-sized firms in the technology and healthcare sectors. He previously served as CFO and head of Business Development for Rimax Health, operating as the Cosmetic Surgery Hospital, as well as Director of Tricounsel Global Investments Fund (TGIF), a "fund of funds". Mr. Polley has also acted in a senior role as Chief Accountant and CFO of Daiwa Securities in Toronto, and was a senior auditor at Arthur Andersen in Toronto. He holds an MBA degree from York University, is a member of the Institute of Chartered Accountants of Ontario and is a graduate of the Canadian Securities Institute.
Biosign's CEO Mr. Robert Kaul stated, "We are very pleased to welcome Mr. Polley to Biosign as our new CFO. He brings us specific healthcare and business development experience which we will need as we move forward with our plans to launch our Heart Friendly™ brand in the US market. Meanwhile, I would like to thank Mr. Iadipaolo for his service to the Company. He has helped guide Biosign through our intense restructuring period, and his dedication, skill, probity and professionalism are greatly appreciated. We wish him all the best in his future endeavours."
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides automated, computer enabled biomedical systems and devices. Key applications include the noninvasive monitoring of vital signs including blood pressure, pulse rate and breathing rate, enhanced with web services. The Company's UFIT® medical device technology powers quality data collection for clinical decision support, self-care, wellness and disease management, while it's Healthanywhere™ Suite offers industry-leading remote patient monitoring solutions. For more information on Biosign, please visit www.biosign.com
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in, Biosign's filings with Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Biosign Technologies Inc.
For further information:
Biosign Contact Information
Robert Kaul, CEO
Biosign Technologies Inc.
Phone: (416) 218-9800 ext. 234